- Also known as
- CJC-1295 DAC · CJC 1295 with drug affinity complex · DAC:GRF · long-acting GHRH analogue
- Class
- Long-acting growth hormone-releasing hormone (GHRH) analogue
- Form
- Lyophilised powder supplied in 5 mg and 10 mg vials
- Sizes
- 5 mg · 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 5 mg: 2 mL · 10 mg: 2 mL
What is CJC-1295 with DAC?
CJC-1295 with DAC is classed as a long-acting growth hormone-releasing hormone (GHRH) analogue, and that classification is the starting point for the published work. The literature on it spans human, mouse and horse models. The same material appears under several names in the literature, among them CJC-1295 DAC, CJC 1295 with drug affinity complex and DAC:GRF. Its recorded sequence is a tetrasubstituted hGRF(1-29) carrying an added N-epsilon-3-maleimidopropionamide lysine at the C-terminus, about 30 residues in all. Of the 6 references below, one is a controlled human trial. We stock it as lyophilised powder in 5 mg and 10 mg vials for laboratory work only. None of it is a medicine; it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Teichman SL et al.2006 · J Clin Endocrinol Metab · PMID 16352683 | Human, two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21-61 (n not stated in the abstract) | Four ascending single s.c. doses, then two or three weekly or fortnightly doses; 30 and 60 micrograms/kg named as better tolerated | 28 and 49 days | One injection raised mean GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days, with a half-life of 5.8-8.1 days. After multiple doses IGF-I stayed above baseline for up to 28 days, and no serious adverse reactions were reported. |
| Ionescu M et al.2006 · J Clin Endocrinol Metab · PMID 17018654 | Human, healthy men aged 20-40 (n not stated in the abstract) | 60 or 90 micrograms/kg, single injection | Overnight sampling before and 1 week after injection | GH secretion rose while pulse frequency and size were unchanged. Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45%, with no difference between the two doses. |
| Sackmann-Sala L et al.2009 · Growth Horm IGF Res · PMID 19386527 | Human, healthy young men (n=11), serum proteomics | Not stated in the abstract | Sera before and 1 week after injection | Two protein spots fell (an apolipoprotein A1 isoform and a transthyretin isoform) and three rose, including beta-haemoglobin and albumin fragments. One spot varied linearly with IGF-1, and the authors propose these as possible biomarkers of GH or IGF-1 action. |
| Jetté L et al.2005 · Endocrinology · PMID 15817669 | Rat (Sprague Dawley) and cultured rat anterior pituitary cells | Not stated in the abstract (s.c.) | Plasma followed beyond 72 h | Albumin conjugates resisted DPP-IV breakdown and stayed active on pituitary cells. CJC-1295 gave a 4-fold larger GH area under the curve over 2 h than hGRF(1-29), bound to albumin within 15 min and was still in plasma beyond 72 h. |
| Alba M et al.2006 · Am J Physiol Endocrinol Metab · PMID 16822960 | Mouse, GHRH knockout (from 1 week of age) | 2 micrograms | 5 weeks, every 24, 48 or 72 h | Daily dosing gave normal body weight and length. Dosing every 48 or 72 h improved growth over placebo without normalising it, and treatment raised pituitary RNA and GH mRNA, with signs of somatotroph proliferation. |
| Timms M et al.2019 · Drug Test Anal · PMID 30489688 | Horse (thoroughbred), assay development and validation | Not stated in the abstract | Not stated in the abstract | An immuno-PCR assay detected the CJC-1295-protein conjugate down to 0.8 pg/mL, with a 50 pg/mL screening threshold in equine plasma. Albumin binding hides the peptide from standard mass-spectrometry peptide screens. |
What these studies don't show: The controlled evidence is genuine, but it is tied to one setting. Trial groups are picked, the endpoints are often surrogate markers rather than real outcomes, and follow-up seldom lasts long. Nothing in it establishes safety beyond the conditions each trial was run under. Knowing the vial contains what the label states is not the same as knowing the compound does anything.
Every study links to its PubMed record. See all CJC-1295 with DAC studies in the research library →
CJC-1295 with DAC price in Canada: 5mg and 10mg vials
Buy CJC-1295 with DAC in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $52.00 | $10.40/mg |
| 10 mg | $72.50 | $7.25/mg |
Starter kit
Is CJC-1295 with DAC available in Canada?
CJC-1295 with DAC is not listed in the Drug Product Database as an authorized product. Health Canada has reached no finding on it, since it has never been submitted for one. It is offered only as research material for lab work, never for use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
Every statement here is linked to the study that recorded it. Any tolerability finding below is quoted straight from the study that reported it. Human work on this scale does not establish a safety profile.
CJC-1295 with DAC FAQ
What is CJC-1295 with DAC?
CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analogue. Its published record is drawn from human, mouse and horse work. Borealis Peptides provides it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. It holds no medicine authorization and is not for use in any living subject. Each reference here appears with the model it ran in and the finding exactly as published.
Where can I buy CJC-1295 with DAC in Canada?
Borealis Peptides dispatches CJC-1295 with DAC from stock held in Canada to research and business addresses across the country. The format is 5 mg and 10 mg vials. HPLC testing covers each batch, and the certificate identifies the batch in your particular vial. We accept orders for laboratory research only.
Is CJC-1295 with DAC legal in Canada?
CJC-1295 with DAC is not listed in the Drug Product Database as an authorized product. Health Canada has reached no finding on it, since it has never been submitted for one. To us it is laboratory research material only, not meant for use in a person or an animal. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so it tells us what the material is supplied for and nothing about permission to use it.
How much CJC-1295 with DAC should I use?
We do not field dosing questions. CJC-1295 with DAC is not provided for use in a person or an animal, so there is no dose to set out. What the page carries is the quantity each cited study used and the model it was used in, reproduced as the authors published it.
What human evidence is there for CJC-1295 with DAC?
One of the 6 cited studies is a controlled trial in people, and the remainder are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.
Does CJC-1295 with DAC need refrigeration?
Keep the sealed vial at −20 °C, away from light and moisture. In solution it sits at 2–8 °C. The dry form is stable at room temperature, so no cold chain is needed in transit; refrigerate on arrival. The genuine risks are repeated freeze-thaw cycles and light exposure, not the shipping itself.
How is the purity of CJC-1295 with DAC confirmed?
Identity and purity are verified by HPLC for each batch, not once per product. The certificate names the batch it covers, and that batch number sits on the vial, so a result can be traced back to the exact material behind it. Ask with your order number and we will send it.
How does CJC-1295 with DAC compare with CJC-1295 (no DAC) and Ipamorelin?
They are distinct compounds with distinct published records, and this site does not rank them. CJC-1295 (no DAC) and Ipamorelin have 6 cited studies and 8 cited studies on their page against 6 here. Place the two evidence tables side by side and the difference shows plainly.
Why is CJC-1295 with DAC named in a Health Canada advisory?
Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. Borealis Peptides provides research material for the laboratory only and markets nothing for injection or for any use in a person, which is precisely the boundary the advisory sets.







